CJC-1295 with DAC
Also known as: CJC-1295 DAC, Drug Affinity Complex CJC
Extended-release GHRH analog with drug affinity complex providing week-long GH elevation.
Evidence
Moderate
FDA status
Not FDA-approved
Source
Synthetic GHRH analog with drug affinity complex
Overview
Extended-release GHRH analog with drug affinity complex providing week-long GH elevation.
Mechanism of Action
GHRH analog with DAC modification binding to albumin for extended half-life (6-8 days), provides sustained GH and IGF-1 elevation, mimics continuous GHRH stimulation rather than pulsatile.
What research has looked at
Effects reported in studies, not proven benefits. See the evidence section below for how strong the research is.
- Long-lasting GH elevation
- Sustained IGF-1 increase
- Muscle growth support
- Improved recovery
- Body composition benefits
Researched for
Research topics, not approved uses.
How Gabriel approaches peptides
Through Gabriel, licensed clinicians may prescribe BPC-157, TB-500, MOTS-c, epitalon and semax (nasal) as compounded medications from licensed 503A pharmacies, under HHS's October 28, 2026 interim policy, and only when appropriate. They are not FDA-approved, and Gabriel never gives peptide dosing. CJC-1295 with DAC isn't prescribed through Gabriel. If you're thinking about it, Gabriel can help you find a licensed clinician to look at the cause of what you're dealing with and the options with stronger evidence.
Research & Evidence
Clinical trials, pharmacokinetic studies
Clinical evidence for sustained GH and IGF-1 elevation. Provides continuous rather than pulsatile GH release, which may be less physiologic than modified GRF (CJC-1295 no DAC).
Safety Information
Potential Side Effects
- •Water retention
- •Increased hunger
- •Numbness/tingling
- •Headache
- •Fatigue
Contraindications
- Active cancer
- Diabetic retinopathy
- Pregnancy
- Breastfeeding
Interactions
- ⚠May affect glucose metabolism
Quick Facts
Related Peptides
CJC-1295
Long-acting GHRH analog that stimulates sustained growth hormone release.
Ipamorelin
Selective ghrelin mimetic that triggers rapid growth hormone release without affecting cortisol or prolactin.
Tesamorelin
Synthetic GHRH analog FDA-approved for reducing visceral adipose tissue in HIV-associated lipodystrophy.